Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors
Significant mortality due to oncological diseases as a whole, and oncohematological diseases in particular, motivates scientific and medical community to develop new treatment methods. One of the newest methods is adoptive cell therapy using patient’s own T-cells modified to express chimeric antigen...
Main Authors: | A. А. Pavlova, M. А. Maschan, V. B. Ponomarev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-04-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/228 |
Similar Items
-
Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
by: Ilnaz Rahimmanesh, et al.
Published: (2021-01-01) -
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
by: Rohtesh S. Mehta, et al.
Published: (2018-02-01) -
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
by: Hiroshi Fujiwara
Published: (2014-12-01) -
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
by: Mohamed-Reda Benmebarek, et al.
Published: (2019-03-01) -
Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell
by: Leila Jafarzadeh, et al.
Published: (2020-06-01)